Zephyr AI Stock
HealthTechLooking to sell Zephyr AI stock or options?
Operator of a healthcare technology company intended to radically rebuild drug discovery and precision medicine from the ground up. The company utilizes large complex data and proprietary algorithms to redefine drug development, streamline clinical trials, battle disease, and clinical decision support, enabling clients to improve quality, outcomes, and costs.
Investors Include:
Lilly USA, Revolution (Washington DC), Jeffrey Skoll, Dubilier & Rice, AME Cloud Ventures, Allen Chao, Verily Life Sciences, BoxGroup, Clayton, Lerner Enterprises.